These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31701536)

  • 1. Siponimod and CYP2C9 Allele Prevalence Among Blacks.
    Liu M; Obeng AO
    J Clin Pharmacol; 2020 Apr; 60(4):429-431. PubMed ID: 31701536
    [No Abstract]   [Full Text] [Related]  

  • 2. Does Siponimod Exert Direct Effects in the Central Nervous System?
    Kipp M
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siponimod to treat secondary progressive multiple sclerosis.
    Gajofatto A; Turatti M
    Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siponimod: First Global Approval.
    Al-Salama ZT
    Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
    Jin Y; Borell H; Gardin A; Ufer M; Huth F; Camenisch G
    Eur J Clin Pharmacol; 2018 Apr; 74(4):455-464. PubMed ID: 29273968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
    Gardin A; Shakeri-Nejad K; Feller A; Huth F; Neelakantham S; Dumitras S
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1565-1574. PubMed ID: 31392364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
    Gardin A; Ufer M; Legangneux E; Rossato G; Jin Y; Su Z; Pal P; Li W; Shakeri-Nejad K
    Clin Pharmacokinet; 2019 Mar; 58(3):349-361. PubMed ID: 30088221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of siponimod: A systematic review.
    Díaz-Villamarín X; Piñar-Morales R; Barrero-Hernández FJ; Antúnez-Rodríguez A; Cabeza-Barrera J; Morón-Romero R
    Biomed Pharmacother; 2022 Sep; 153():113536. PubMed ID: 36076616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis].
    Calfunao S; Carrasco M; Gutierrez C; Cerpa L; Varela N; Quiñones L
    Rev Med Chil; 2023 Oct; 151(10):1375-1384. PubMed ID: 39093141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.
    Vogelgesang A; Domanska G; Ruhnau J; Dressel A; Kirsch M; Schulze J
    Stroke; 2019 May; 50(5):1224-1231. PubMed ID: 31009359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siponimod Chips Away at Progressive MS.
    Longbrake EE; Hafler DA
    Cell; 2019 Dec; 179(7):1440. PubMed ID: 31951523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards treating progressive multiple sclerosis.
    Thompson A; Ciccarelli O
    Nat Rev Neurol; 2020 Nov; 16(11):589-590. PubMed ID: 33024328
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.
    Song Y; Lao Y; Liang F; Li J; Jia B; Wang Z; Hui X; Lu Z; Zhou B; Luo W; Song B
    Medicine (Baltimore); 2019 Aug; 98(34):e15415. PubMed ID: 31441835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
    Gajofatto A
    Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
    Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
    Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.